Evidence map›Paper›PMID 40530413›Full record

ReviewBioactive materials2025

Antiviral nanomedicine: Advantages, mechanisms and advanced therapies.

Yicheng Pu, Chuanda Zhu, Jun Liao, Lidong Gong, Yijuan Wu, Shunquan Liu, Hongjun Wang, Qiang Zhang, Zhiqiang Lin

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Bioactive materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yicheng PuInstitute of Systems Biomedicine, Beijing Key Laboratory of Tumor Systems Biology, School of Basic Medical Sciences, Peking University, Beijing 100191, China.
Chuanda ZhuDepartment of Biophysics, Peking University Health Science Center, Beijing 100191, China.
Jun LiaoInstitute of Systems Biomedicine, Beijing Key Laboratory of Tumor Systems Biology, School of Basic Medical Sciences, Peking University, Beijing 100191, China.
Lidong GongInstitute of Systems Biomedicine, Beijing Key Laboratory of Tumor Systems Biology, School of Basic Medical Sciences, Peking University, Beijing 100191, China.
Yijuan WuInstitute of Systems Biomedicine, Beijing Key Laboratory of Tumor Systems Biology, School of Basic Medical Sciences, Peking University, Beijing 100191, China.
Shunquan LiuSchool of Physics, Peking University, Beijing 100091, China.
Hongjun WangBeijing Tide Pharmaceutical Co., Ltd, Beijing 100176, China.
Qiang ZhangDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Zhiqiang LinInstitute of Systems Biomedicine, Beijing Key Laboratory of Tumor Systems Biology, School of Basic Medical Sciences, Peking University, Beijing 100191, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of novel viral pathogens and the limitations of conventional antiviral therapies necessitate innovative strategies to combat persistent and pandemic threats. This review details the role of viral infections and antiviral nanomedicines, delving into the mechanisms of action and antiviral advantages of nanomedicines, as well as the latest research advances in this field. The review systematically categorizes the mechanisms of antiviral nanodrugs into a framework that integrates previously fragmented knowledge, and innovatively summarizes the unique attributes and advantages of antiviral nanodrugs compared to small-molecule drugs. Nanotherapies are proposed in this review to conclude advanced nanoantivirals (e.g., light-activated nanophotosensitizers, biomimetic decoys, PROTAC-based degraders, and gene-silencing platforms) and offer a distinctive narrative perspective, with the aim of presenting a merged and integrated overview of nanodrugs. By intuitively highlighting their commonalities in mechanisms or similarities in application methods, readers may better appreciate the innovative characteristics of different antivirals. We further discuss translational challenges and propose interdisciplinary solutions and future directions to accelerate the development of next-generation antiviral strategies. This review aims to inspire transformative research at the nexus of virology, nanotechnology, and precision medicine.

Indexed as

Antiviral nanomedicineBiomimetic nanomaterialsNanotechnologyTargeted drug deliveryVirus-host interaction

Identifiers

PMID40530413
PMCPMC12173073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.